Genome Medicine (Jan 2024)

The impact of damaging epilepsy and cardiac genetic variant burden in sudden death in the young

  • Megan J. Puckelwartz,
  • Lorenzo L. Pesce,
  • Edgar J. Hernandez,
  • Gregory Webster,
  • Lisa M. Dellefave-Castillo,
  • Mark W. Russell,
  • Sarah S. Geisler,
  • Samuel D. Kearns,
  • Felix Karthik,
  • Susan P. Etheridge,
  • Tanner O. Monroe,
  • Tess D. Pottinger,
  • Prince J. Kannankeril,
  • M. Benjamin Shoemaker,
  • Darlene Fountain,
  • Dan M. Roden,
  • Meghan Faulkner,
  • Heather M. MacLeod,
  • Kristin M. Burns,
  • Mark Yandell,
  • Martin Tristani-Firouzi,
  • Alfred L. George,
  • Elizabeth M. McNally

DOI
https://doi.org/10.1186/s13073-024-01284-w
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Sudden unexpected death in children is a tragic event. Understanding the genetics of sudden death in the young (SDY) enables family counseling and cascade screening. The objective of this study was to characterize genetic variation in an SDY cohort using whole genome sequencing. Methods The SDY Case Registry is a National Institutes of Health/Centers for Disease Control and Prevention surveillance effort to discern the prevalence, causes, and risk factors for SDY. The SDY Case Registry prospectively collected clinical data and DNA biospecimens from SDY cases < 20 years of age. SDY cases were collected from medical examiner and coroner offices spanning 13 US jurisdictions from 2015 to 2019. The cohort included 211 children (median age 0.33 year; range 0–20 years), determined to have died suddenly and unexpectedly and from whom DNA biospecimens for DNA extractions and next-of-kin consent were ascertained. A control cohort consisted of 211 randomly sampled, sex- and ancestry-matched individuals from the 1000 Genomes Project. Genetic variation was evaluated in epilepsy, cardiomyopathy, and arrhythmia genes in the SDY and control cohorts. American College of Medical Genetics/Genomics guidelines were used to classify variants as pathogenic or likely pathogenic. Additionally, pathogenic and likely pathogenic genetic variation was identified using a Bayesian-based artificial intelligence (AI) tool. Results The SDY cohort was 43% European, 29% African, 3% Asian, 16% Hispanic, and 9% with mixed ancestries and 39% female. Six percent of the cohort was found to harbor a pathogenic or likely pathogenic genetic variant in an epilepsy, cardiomyopathy, or arrhythmia gene. The genomes of SDY cases, but not controls, were enriched for rare, potentially damaging variants in epilepsy, cardiomyopathy, and arrhythmia-related genes. A greater number of rare epilepsy genetic variants correlated with younger age at death. Conclusions While damaging cardiomyopathy and arrhythmia genes are recognized contributors to SDY, we also observed an enrichment in epilepsy-related genes in the SDY cohort and a correlation between rare epilepsy variation and younger age at death. These findings emphasize the importance of considering epilepsy genes when evaluating SDY.

Keywords